title: αvβ1 integrin as a novel therapeutic target for tissue fibrosis.
abstract: Chronic tissue injury with fibrosis results in disruption of tissue architecture, organ dysfunction and eventually organ failure. Currently, therapeutic options for tissue fibrosis are severely limited and organ transplantation including high cost and co-morbidities is the only effective treatment for end-stage fibrotic disease. Therefore, it is imperative to develop effective anti-fibrotic agents. Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis. In this perspective, we reviewed the functions of αvβ1 integrin as a potentially useful target molecule for antifibrotic agent and introduced novel specific small-molecule inhibitors targeting this integrin.
authors.affiliation: Division of Applied Radiation Bioscience, Korea Institute of Radiological & Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.
authors.forename: Kyung-Hee
authors.initials: KH
authors.lastname: Song
authors.affiliation: Division of Applied Radiation Bioscience, Korea Institute of Radiological & Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.
authors.forename: Seong-Jun
authors.initials: SJ
authors.lastname: Cho
authors.affiliation: Division of Applied Radiation Bioscience, Korea Institute of Radiological & Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.
authors.forename: Jie-Young
authors.initials: JY
authors.lastname: Song
keywords: Integrin; fibrosis; small-molecule inhibitor; transforming growth factor-beta